| Nhc Healthcare, Dickson | |
| 812 Charlotte St, Dickson, Tennessee 37055 | |
| (615) 446-8046 | |
| Name | Nhc Healthcare, Dickson |
|---|---|
| Location | 812 Charlotte St, Dickson, Tennessee |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 191 |
| Occupancy Rate | 85.18% |
| Medicare ID (CCN) | 445004 |
| Legal Business Name | Nhc Healthcare-dickson Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1699713164 |
| Organization Name | NHC HEALTHCARE-DICKSON LLC |
| Address | 812 N Charlotte St, Dickson, TN 37055 |
| Phone Number | 615-446-8046 |
News Archive
AstraZeneca and its global biologics research and development arm, MedImmune, will report new clinical trial and scientific data from their industry-leading lung cancer franchise of marketed and pipeline medicines at the European Lung Cancer Conference in Geneva, Switzerland, 13 -16 April 2016.
While cancer survivors require follow-up care to prevent a recurrence of their cancer and to watch for after effects of treatment, they also need the same preventive check-ups suggested for all people.
ResMed Inc. today announced the launch of the first product in Japan using technology from its recently acquired company, BiancaMed. The product, launched by BiancaMed partner Omron Healthcare, is a new wireless sleep monitoring device.
A large proportion of patients who have undergone cancer treatment go on to suffer from chronic fatigue. A new online intervention, which uses an activity tracker and a standard smartphone, has brought significant improvement in 66% of cases, while 21% of patients report a complete recovery.
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
AstraZeneca and its global biologics research and development arm, MedImmune, will report new clinical trial and scientific data from their industry-leading lung cancer franchise of marketed and pipeline medicines at the European Lung Cancer Conference in Geneva, Switzerland, 13 -16 April 2016.
While cancer survivors require follow-up care to prevent a recurrence of their cancer and to watch for after effects of treatment, they also need the same preventive check-ups suggested for all people.
ResMed Inc. today announced the launch of the first product in Japan using technology from its recently acquired company, BiancaMed. The product, launched by BiancaMed partner Omron Healthcare, is a new wireless sleep monitoring device.
A large proportion of patients who have undergone cancer treatment go on to suffer from chronic fatigue. A new online intervention, which uses an activity tracker and a standard smartphone, has brought significant improvement in 66% of cases, while 21% of patients report a complete recovery.
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 20.22 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 11.11 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 56.12 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.35 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.87 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.78 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.57 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 19 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 99.59 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.77 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 39.04 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 27.48 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.25 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.34 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 93.4 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 96.73 | 82.93 |
News Archive
AstraZeneca and its global biologics research and development arm, MedImmune, will report new clinical trial and scientific data from their industry-leading lung cancer franchise of marketed and pipeline medicines at the European Lung Cancer Conference in Geneva, Switzerland, 13 -16 April 2016.
While cancer survivors require follow-up care to prevent a recurrence of their cancer and to watch for after effects of treatment, they also need the same preventive check-ups suggested for all people.
ResMed Inc. today announced the launch of the first product in Japan using technology from its recently acquired company, BiancaMed. The product, launched by BiancaMed partner Omron Healthcare, is a new wireless sleep monitoring device.
A large proportion of patients who have undergone cancer treatment go on to suffer from chronic fatigue. A new online intervention, which uses an activity tracker and a standard smartphone, has brought significant improvement in 66% of cases, while 21% of patients report a complete recovery.
› Verified 9 days ago